CANbridge Pharmaceuticals 관리

관리 기준 확인 2/4

CANbridge Pharmaceuticals CEO는 James Qun Xue, Jan2018 에 임명되었습니다 의 임기는 6.83 년입니다. 총 연간 보상은 CN¥ 9.55M, 59.8% 로 구성됩니다. 59.8% 급여 및 40.2% 보너스(회사 주식 및 옵션 포함). 는 € 662.43K 가치에 해당하는 회사 주식의 9.85% 직접 소유합니다. 662.43K. 경영진과 이사회의 평균 재임 기간은 각각 2.5 년과 2.8 년입니다.

주요 정보

James Qun Xue

최고 경영자

CN¥9.5m

총 보상

CEO 급여 비율	59.8%
CEO 임기	6.8yrs
CEO 소유권	9.9%
경영진 평균 재임 기간	2.5yrs
이사회 평균 재임 기간	2.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

James Qun Xue 의 보수는 CANbridge Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-CN¥408m
Mar 31 2024	n/a	n/a	-CN¥393m
Dec 31 2023	CN¥10m	CN¥6m	-CN¥379m
Sep 30 2023	n/a	n/a	-CN¥416m
Jun 30 2023	n/a	n/a	-CN¥453m
Mar 31 2023	n/a	n/a	-CN¥468m
Dec 31 2022	CN¥13m	CN¥5m	-CN¥483m
Sep 30 2022	n/a	n/a	-CN¥733m
Jun 30 2022	n/a	n/a	-CN¥982m
Mar 31 2022	n/a	n/a	-CN¥1b
Dec 31 2021	CN¥10m	CN¥4m	-CN¥1b
Sep 30 2021	n/a	n/a	-CN¥1b
Jun 30 2021	n/a	n/a	-CN¥1b
Mar 31 2021	n/a	n/a	-CN¥828m
Dec 31 2020	CN¥6m	CN¥4m	-CN¥846m
Dec 31 2019	CN¥10m	CN¥3m	-CN¥218m

보상 대 시장: James Qun 의 총 보상 ($USD 1.32M )은 German 시장( $USD 475.63K ).

보상과 수익: James Qun 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

James Qun Xue (54 yo)

6.8yrs

테뉴어

CN¥9,545,000

보상

Dr. James Qun Xue, Ph D., M.B.A., has served as Chairman of the Board and Chief Executive Officer at CANbridge Pharmaceuticals Inc. since January 2018 and as an executive Director on June 21, 2021 and serv...

리더십 팀

이름	위치	테뉴어	보상	소유권
James Qun Xue	Founder	6.8yrs	CN¥9.55m	9.85% € 662.4k
Qian Ma	General Counsel	3.4yrs	데이터 없음	데이터 없음
Stella Mao	Vice President of Public Affairs	4.8yrs	데이터 없음	데이터 없음
Chris Chen	Vice President of Human Resources	no data	데이터 없음	데이터 없음
Gerald F. Cox	Chief Development Strategist & Interim Chief Medical Officer	5.3yrs	데이터 없음	데이터 없음
Pauline Li	Chief Medical Officer	no data	데이터 없음	데이터 없음
Rebecca Zhang	Senior Vice President of Regulatory Affairs	2.3yrs	데이터 없음	데이터 없음
Jeff Kou	Director and Head of Program Management & Clinical Operations	2.8yrs	데이터 없음	데이터 없음
Fannie Man	Mainland China Commercial Head & GM of Hong Kong and Macau	1.3yrs	데이터 없음	데이터 없음
Jason West	Head of Global Gene Therapy Research	no data	데이터 없음	데이터 없음
Joe Shen	Senior Vice President	less than a year	데이터 없음	데이터 없음
Will Wang	Senior Director & Head of Production	no data	데이터 없음	데이터 없음

2.5yrs

평균 재임 기간

경험이 풍부한 관리: MF1 의 관리팀은 경험 ( 2.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
James Qun Xue	Founder	6.8yrs	CN¥9.55m	9.85% € 662.4k
James Arthur Geraghty	Independent Non-Executive Director	6.3yrs	CN¥317.00k	0.16% € 11.1k
Peng Kuan Chan	Independent Non-Executive Director	3.4yrs	CN¥317.00k	데이터 없음
Richard Gregory	Independent Non-Executive Director	4.6yrs	CN¥317.00k	데이터 없음
Guangping Gao	Member of Strategic Advisory Board	4.4yrs	데이터 없음	데이터 없음
Mark A. Goldberg	Member of Strategic Advisory Board	no data	데이터 없음	데이터 없음
Anthony Amato	Member of Scientific Advisory Board	2.3yrs	데이터 없음	데이터 없음
Richard Polisson	Member of Scientific Advisory Board	2.3yrs	데이터 없음	데이터 없음
Lan Hu	Independent Non-Executive Director	2.8yrs	CN¥320.00k	데이터 없음
Robert Colvin	Member of Scientific Advisory Board	2.3yrs	데이터 없음	데이터 없음
Jean Francis	Member of Scientific Advisory Board	2.3yrs	데이터 없음	데이터 없음
Sushrut Waikar	Member of Scientific Advisory Board	2.3yrs	데이터 없음	데이터 없음

2.8yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: MF1 의 이사회는 경험(평균 재직 기간 2.8 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

CANbridge Pharmaceuticals 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

CANbridge Pharmaceuticals Inc. Announces Board and Board Committee Changes

CANbridge Pharmaceuticals Inc. Announces Resignation of Derek Paul Di Rocco as Non-Executive Director and A Member of the Nomination and Corporate Governance Committee

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

CANbridge Pharmaceuticals Inc. Forms Scientific Advisory Board

Recent updates

First half 2024 earnings released: CN¥0.58 loss per share (vs CN¥0.51 loss in 1H 2023)

CANbridge Pharmaceuticals Inc. Announces Board and Board Committee Changes

CANbridge Pharmaceuticals Inc. to Report First Half, 2024 Results on Aug 29, 2024

Full year 2023 earnings released: CN¥0.89 loss per share (vs CN¥1.14 loss in FY 2022)

CANbridge Pharmaceuticals Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

CANbridge Pharmaceuticals Inc. Announces Resignation of Derek Paul Di Rocco as Non-Executive Director and A Member of the Nomination and Corporate Governance Committee

CANbridge Pharmaceuticals Inc. to Present Fabry Disease Gene Therapy Abstract At Esgct 30Th Annual Congress

CANbridge Announces NDA Acceptance of CAN108 (???®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) by China's National Medical Products Administration

Canbridge Pharmaceuticals Inc. Announces Full Enrollment Reached in the Core Part of the Can103 Phase 2 Trial for Gaucher Disease in China

Canbridge Pharmaceuticals Inc. Announces Marketing Approval of Can108 (Maralixibat Chloride Oral Solution /Livmarli®?) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (Algs)

First half 2023 earnings released: CN¥0.51 loss per share (vs CN¥0.59 loss in 1H 2022)

High number of new and inexperienced directors

CANbridge Pharmaceuticals Inc. to Report First Half, 2023 Results on Aug 30, 2023

CANbridge Pharmaceuticals Inc. Announces Preliminary Clinical Data of Phase 1B Study of Omoprubart (CAN106) in Paroxysmal Nocturnal Hemoglobinuria (PNH)

CANbridge Pharmaceuticals, Inc. Announces Marketing Approval of CAN108 (LIVMARLI) in China for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome

CANbridge Pharmaceuticals Inc. Announces Full Enrollment Reached in China Region of the Global LIVMARLI(R) (CAN108) EMBARK Phase 2 Study in Biliary Atresia

Full year 2022 earnings released: CN¥1.14 loss per share (vs CN¥11.43 loss in FY 2021)

CANbridge Pharmaceuticals Inc. Announces First Patient Dosed in CAN103 Phase 2 Trial for the Treatment of Gaucher Disease in China

High number of new and inexperienced directors

High number of new and inexperienced directors

First half 2022 earnings released: CN¥0.59 loss per share (vs CN¥46.79 loss in 1H 2021)

CANbridge Pharmaceuticals Inc. to Report First Half, 2022 Results on Aug 24, 2022

Canbridge Pharmaceuticals Inc. Announces First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 1/2 Trial for the Treatment of Gaucher Disease in China

CANbridge Pharmaceuticals Inc. Announces First Patient Dosed in CAN108 (Maralixibat) EMBARK Phase 2 Study in Biliary Atresia in China

CANbridge Pharmaceuticals Inc. Forms Scientific Advisory Board

Canbridge Pharmaceuticals Inc. Announces Board Changes

High number of new and inexperienced directors

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간

평균 연령